Update on the diagnosis and treatment of prostate cancer.
Our understanding of the causes of prostate cancer and improvements in screening methodologies and risk assessment prior to definitive local therapy continue to be refined. The utility of hormone therapy has been further evaluated, both as adjuvant and neoadjuvant therapy with radiation therapy or radical prostatectomy, as well as for patients with more advanced disease. Finally, modest inroads continue to be made in the treatment and understanding of hormone-refractory prostate cancer.
Small
E J
EJ
University of California, San Francisco, Mount Zion Cancer Center 94115, USA.
D000328:Adult; D000368:Aged; D000728:Androgens; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004041:Dietary Fats / Q000009:adverse effects; D004198:Disease Susceptibility; D019008:Drug Resistance, Neoplasm; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D009386:Neoplastic Syndromes, Hereditary / Q000453:epidemiology / Q000235:genetics; D009857:Oncogenes; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D012372:ROC Curve; D011867:Radioisotope Teletherapy / Q000009:adverse effects; D018570:Risk Assessment; D016879:Salvage Therapy
D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D004041:Dietary Fats; D006727:Hormone Antagonists; D009363:Neoplasm Proteins; D017430:Prostate-Specific Antigen